Buspirone induced prolactin responses in obsessive—compulsive disorder (OCD)

Jv, Lucey; Butcher, Gerard; Aw, Clare; Tg, Dinan

doi:10.1097/00004850-199200710-00006

Cited by 10 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To dissect the mechanism of action underlying the OCD symptoms inducing properties of mCPP, studies with more selective agents are warranted. Several agents have already been tested, including ipsapirone and buspirone (5-HT IA receptor agonists) (Lesch et al 1991;Lucey et al 1992;Pigott et al 1992), ondansetron (5-HT 3 antagonist) (Broocks et al 1992) and MK-212 (5-HT 1A , 5-HT 1B and 5-HT 2C receptor agonist) (Bastani et al 1990). All were found to be ine¤ective in inducing obsessive compulsive symptoms.…”

Section: Introductionmentioning

confidence: 99%

Sumatriptan (5-HT 1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder

Pian¹,

Westerberg²,

Megen³

et al. 1998

Psychopharmacology

View full text Add to dashboard Cite

The non-selective serotonin (5-HT) receptor agonist meta-chlorophenylpiperazine (mCPP) has been reported to elicit symptoms in patients with obsessive compulsive disorder (OCD). MK-212, another non-selective 5-HT receptor agonist, does not seem to induce obsessive compulsive symptoms in OCD patients. The major pharmacological difference between mCPP and MK-212 is their affinity for the 5-HT(ID) receptor. The aim of this study was to explore the role of the 5-HT(ID) receptor in the pathophysiology of OCD, by using a challenge paradigm with the selective 5-HT(ID) receptor agonist sumatriptan (Imigran). A randomized, double-blind, placebo-controlled crossover challenge with sumatriptan (100 mg PO) was performed in 15 OCD patients. Neither the obsessive compulsive symptoms nor mood or anxiety symptoms changed significantly following sumatriptan administration as compared to placebo. Sumatriptan did induce a significant increase in plasma growth hormone (GH) levels. In the present study, no indication were found for the role of the 5-HT(ID) receptor in the pathophysiology of OCD. It should be noted, however, that sumatriptan does not readily pass the blood-brain barrier. Selective 5-HT(ID) receptors with better brain penetrating properties may shed more light on the role of this 5-HT receptor subtype in OCD.

show abstract

Section: Introductionmentioning

confidence: 99%

Sumatriptan (5-HT 1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder

Pian¹,

Westerberg²,

Megen³

et al. 1998

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Similar blunted responses to fenfluramine challenge have been reported in depressed patients (12,15). Considering the fact that the prolactin response to fenfluramine is mediated through 5-HT receptors -subtype 2A and 2C, it is conceivable that these receptor subtypes are involved in the pathogenesis of OCD (13). The notion of altered sensitivity is, not easily explained in therm of a super-or subsensitivity.…”

Section: Discussionmentioning

confidence: 64%

Fenfluramine Challenge Test in Obsessive-Compulsive Disorder - First Results

Pidrman¹,

Tůma²

1997

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

Obsessive-compulsive disorder is a chronic psychiatric illness, affecting up to 3% of the general population, to the midle of 60-th it was supposed to be untreatable. Antidepressant pharmacotherapy is one of the treatment alternatives today. We compared efficacy and safety of citalopram versus clomipramine (serotoninergic antidepressants) in 6 weeks in double blind therapy of obsessive-compulsive disorder. The second objective was to compare prolactin response to a fenfluramine challenge test before the treatment of patients and after 6 weeks of the treatment. In a sample of 14 patients we confirmed significant therapeutic response after 3 weeks of pharmacoterapy, better in obsession than in compulsion. We found low level of adverse effects in the first week of therapy - dry mouth, anxiety, nausea, somnolence, tremor, and sexual adverse events. There were no changes in the laboratory, test EEG, and ECG examinations. Fenfluramine challenge test showed statistically significant decrease of prolactine levels 1 hour after administration of fenfluramine. It was not observed after six weeks of the therapy. Statistically significant negative correlation between prolactine plasma levels at the 6-th hour after administration of fenfluramine and obsession item of YBOC Scale was showed after the 3-rd and 6-th week of the therapy. The correlation was not observed for compulsion item YBOC Scale. Side effects observed during and after the challenge test were anxiety and nervousness and gastrointestinal problems, lasted from l hour to 10 hours. These preliminary result could support the idea, that obsessions and compulsions have not necessary the same biological background. The challenge paradigm appears to be a possible way to clarify the pathogenesis of OCD. Our study will continue.

show abstract

“…The PRL responses in the OCD sample (321 + 98 mU/1) and in the controls (291 +50 mU/1) were not significantly different [F= (1,87) 0.75, p = 0.75 ]. Allowing for the possibility of a type 2 error, the data do not suggest that the central 5-HT attenuation in OCD involves dysfunction at the 5-HT,A receptor(Lucey et al, 1992b).…”

mentioning

confidence: 55%

BAP/SKB Young Psychopharmacologist Award Towards a neuroendocrinology of obsessive-compulsive disorder

Lucey¹

1994

J Psychopharmacol

View full text Add to dashboard Cite

Neuroendocrine research has made an important contribution to the understanding of psychiatric illness in vivo. This review is a summary of the recent neuroendocrine studies on obsessive-compulsive disorder (OCD) patients carried out at the Departments of Psychiatry at Trinity College Medical School and St. Patrick's Hospital, Dublin, Ireland. We found that both serotonergic and cholinergic abnormalities were present in OCD, while noradrenergic responsivity and hypothalmic-pituitary axis function were normal. The data suggests that OCD may have a unique neuroendocrinology.

show abstract

Buspirone induced prolactin responses in obsessive—compulsive disorder (OCD)

Cited by 10 publications

References 0 publications

Sumatriptan (5-HT 1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder

Sumatriptan (5-HT 1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder

Fenfluramine Challenge Test in Obsessive-Compulsive Disorder - First Results

BAP/SKB Young Psychopharmacologist Award Towards a neuroendocrinology of obsessive-compulsive disorder

Contact Info

Product

Resources

About